CytomX Therapeutics 将来の成長

Future 基準チェック /06

CytomX Therapeuticsの収益と利益はそれぞれ年間17.2%と39.9%減少すると予測されていますが、EPS は年間41% 減少すると予測されています。

主要情報

-39.9%

収益成長率

-41.0%

EPS成長率

Biotechs 収益成長	27.6%
収益成長率	-17.2%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	21 Nov 2024

今後の成長に関する最新情報

Recent updates

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Bounce 26% But Its Business Still Trails The Industry

Dec 17

Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues

Oct 26

CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments

Jul 15

The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

Jun 15

We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

May 09

CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling

May 02

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

Apr 27

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

Apr 25

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

Mar 05

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Jan 19

There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

Nov 26

We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Nov 17

Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 29

Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?

Feb 13

Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

Nov 10

CytomX Therapeutics to cut workforce by about 40%

Jul 13

CytomX says phase 2 study of breast cancer antibody treatment met main goal

Jul 06

Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Jun 08

Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?

Feb 10

CytomX: Pullbacks Are Opportunities

Dec 14

業績と収益の成長予測

NasdaqGS:CTMX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	45	-76	-28	N/A	3
12/31/2025	81	-32	-13	-40	6
12/31/2024	116	-8	-50	-69	6
9/30/2024	127	14	-89	-88	N/A
6/30/2024	120	11	-86	-86	N/A
3/31/2024	119	17	-92	-91	N/A
12/31/2023	101	-1	-57	-56	N/A
9/30/2023	95	-10	-36	-35	N/A
6/30/2023	79	-42	-52	-51	N/A
3/31/2023	68	-71	-61	-60	N/A
12/31/2022	53	-99	-113	-111	N/A
9/30/2022	21	-149	-142	-141	N/A
6/30/2022	27	-143	-138	-136	N/A
3/31/2022	30	-132	-132	-130	N/A
12/31/2021	37	-116	-121	-119	N/A
9/30/2021	66	-72	-107	-105	N/A
6/30/2021	66	-64	-103	-100	N/A
3/31/2021	67	-61	23	25	N/A
12/31/2020	68	-65	3	5	N/A
9/30/2020	92	-54	-9	-7	N/A
6/30/2020	85	-63	-8	-5	N/A
3/31/2020	78	-76	-154	-151	N/A
12/31/2019	27	-133	-144	-140	N/A
9/30/2019	61	-99	-144	-140	N/A
6/30/2019	62	-99	-126	-122	N/A
3/31/2019	75	-83	-105	-100	N/A
12/31/2018	60	-85	-79	-76	N/A
9/30/2018	75	-52	-28	-25	N/A
6/30/2018	87	-39	N/A	-25	N/A
3/31/2018	74	-50	N/A	175	N/A
12/31/2017	72	-43	N/A	170	N/A
9/30/2017	51	-58	N/A	150	N/A
6/30/2017	30	-62	N/A	142	N/A
3/31/2017	24	-51	N/A	-16	N/A
12/31/2016	15	-59	N/A	-2	N/A
9/30/2016	11	-57	N/A	-12	N/A
6/30/2016	9	-57	N/A	-6	N/A
3/31/2016	8	-50	N/A	-28	N/A
12/31/2015	8	-42	N/A	-27	N/A
9/30/2015	8	-36	N/A	-24	N/A
6/30/2015	8	-26	N/A	30	N/A
3/31/2015	6	-24	N/A	31	N/A
12/31/2014	5	-35	N/A	32	N/A
12/31/2013	1	-19	N/A	-8	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CTMXの収益は今後 3 年間で減少すると予測されています (年間-39.9% )。

収益対市場: CTMXの収益は今後 3 年間で減少すると予測されています (年間-39.9% )。

高成長収益: CTMXの収益は今後 3 年間で減少すると予測されています。

収益対市場: CTMXの収益は今後 3 年間で減少すると予想されています (年間-17.2% )。

高い収益成長: CTMXの収益は今後 3 年間で減少すると予測されています (年間-17.2% )。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CTMXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2024/12/22 03:26
終値	2024/12/20 00:00
収益	2024/09/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

CytomX Therapeutics, Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。17

アナリスト	機関
Peter Lawson	Barclays
Etzer Darout	BMO Capital Markets Equity Research
Ying Huang	BofA Global Research

CytomX Therapeutics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Consensus estimates of losses per share improve by 61%

Consensus revenue estimates increase by 13%

Consensus EPS estimates upgraded to US$0.29 loss

Consensus EPS estimates fall by 138%

Consensus EPS estimates fall by 35%

Consensus EPS estimates fall by 29%

Recent updates

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Bounce 26% But Its Business Still Trails The Industry

Investor sentiment improves as stock rises 17%

Consensus estimates of losses per share improve by 61%

Consensus revenue estimates increase by 13%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

CytomX Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues

Investor sentiment improves as stock rises 17%

Consensus EPS estimates upgraded to US$0.29 loss

Consensus EPS estimates fall by 138%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorates as stock falls 16%

New minor risk - Market cap size

CytomX Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments

CytomX Therapeutics, Inc. Promotes Chris Ogden to Chief Financial Officer

The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

Investor sentiment deteriorates as stock falls 16%

Consensus EPS estimates fall by 35%

Investor sentiment deteriorates as stock falls 53%

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

Consensus EPS estimates fall by 29%

Price target increased by 47% to US$4.00

CytomX Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

CytomX Therapeutics, Inc. Announces First Patient Dosed with CX-2051, A Conditionally Activated EpCAM-Directed ADC, in A Phase 1 Study in Patients with Advanced Solid Tumors

CytomX Therapeutics, Inc., Annual General Meeting, May 15, 2024

Chairman & CEO exercised options to buy US$239k worth of stock.

Consensus estimates of losses per share improve by 43%

CytomX Therapeutics, Inc. Appoints Dr. Zhen Su to Board of Directors

Consensus revenue estimates increase by 12%, EPS downgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

CytomX Therapeutics, Inc. to Report Q4, 2023 Results on Mar 11, 2024

Price target increased by 9.6% to US$2.73

New minor risk - Market cap size

CytomX Therapeutics, Inc. Announces FDA Clearance of IND Applications for CX-2051, a Probody Antibody Drug Conjugate Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

New minor risk - Profitability

Forecast breakeven date pushed back to 2024

There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

Consensus EPS estimates fall by 72%

We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2023

CytomX Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

CytomX Therapeutics, Inc. Presents Preclinical Profile of EpCAM-Directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference

New minor risk - Market cap size

CytomX Therapeutics, Inc. announced that it has received $30 million in funding

Consensus revenue estimates increase by 18%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

CytomX Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

CytomX Therapeutics, Inc. Appoints Yu-Waye Chu as Chief Medical Officer

New minor risk - Market cap size

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to US$0.66 loss

Full year 2022 earnings: EPS and revenues miss analyst expectations

Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts

Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?

Price target decreased to US$3.31

High number of new and inexperienced directors

Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

CytomX Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

CytomX Therapeutics, Inc. Announces Executive Changes